Abstract
This document represents the official position of the American Association of Clinical Endocrinologists and the American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.
Publication types
-
Consensus Development Conference
MeSH terms
-
Blood Glucose / analysis*
-
Blood Glucose Self-Monitoring* / instrumentation
-
Blood Glucose Self-Monitoring* / methods
-
Consensus
-
Cost-Benefit Analysis
-
Diabetes Mellitus, Type 1 / blood*
-
Diabetes Mellitus, Type 1 / drug therapy
-
Endocrinology*
-
Glycated Hemoglobin / analysis
-
Humans
-
Hypoglycemia / blood
-
Hypoglycemia / prevention & control
-
Hypoglycemic Agents / therapeutic use
-
Insulin Infusion Systems / economics
-
Insurance, Health, Reimbursement / legislation & jurisprudence
-
Legislation as Topic
-
Sensitivity and Specificity
-
Societies, Medical
-
Time Factors
-
United States
Substances
-
Blood Glucose
-
Glycated Hemoglobin A
-
Hypoglycemic Agents